Evaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapy

Abstract

Molecular analysis is key to a better understanding of drug resistance during therapy. The aim of this study was to evaluate changes in the expression of tumor necrosis factor α (TNF‐α), interleukin (IL)—IL12A, IL12B, IL23A, interferon gamma (IFN‐γ) in psoriatic patients during 84 days of treatment and TNF‐α on the protein level. The study group consisted of 32 psoriatic patients during cyclosporine A therapy. The molecular analysis was made by using real‐time reverse transcription polymerase chain assay (RTqPCR) and MALDI ToF mass spectroscopy three times: after 0, 42, 84 days of treatment. Statistically significant differences (p < .05) in transcriptional activity were observed for genes: TNF‐α (0 vs. 42nd days p = .006; 0 vs. 84th days p = .005), IL23A (0 vs. 42nd days p = .041), IFN‐γ (0 vs. 42th days p = .040; 0 vs. 84th days p = .041), IL17 (0 vs. 42nd p = .000003 0 vs. 84th p = .001650), IL12A (0 vs. 42nd p = .0047 vs. 84th p = .0063). The expression of TNF‐α was downregulated during therapy, IL23A was upregulated during CsA treatment, while the expression of IFN‐γ and IL17 were higher after 42 days and lower after 84 days compared to 0 days of CsA treatment. It seems that TNF‐α, IL12A, IL23A, IFN‐γ, and IL17 can be useful complementary molecular markers to assess the efficacy of psoriasis treatment.

Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine

“…Additional pharmacotranscriptomic approaches in the CsA treatment revealed the molecular reversion of several cytokine levels [ 58 , 59 ] and transforming growth factor (TGF)-β isoforms [ 60 ], with the former study further displaying the reduction of K16 + , CD3 + , and CD25 + cells in the lesional skin [ 58 ]. Furthermore, immunohistochemical staining for TNF and ICAM-1 of psoriatic skin was significantly reduced after CsA treatment approaching non-lesional levels [ 61 ].…”